The company focuses on the development, research, production and sales of therapeutic drugs for cardiovascular and cerebrovascular diseases and metabolic diseases. The leading product of the company is breviscapine freeze-dried powder injection for Jinlong injection. Over the years, the company has devoted itself to the in-depth study of the formula and preparation technology of breviscapine for injection, and mastered the relevant core technologies. The quality standard of breviscapine for injection drafted by the company has been included in China Pharmacopoeia, and it is the only monomer preparation with a purity of 98%.
The company obtained 17 national invention patents from raw materials to preparations. At present, the company has nearly 30 invention patents at home and abroad. At present, the company's production and operation are in good condition. It is a fast-growing high-tech pharmaceutical enterprise in Yunnan Province, a top non-public enterprise in Yunnan Province 100, a leading enterprise in strategic emerging industries in Yunnan Province, and a pilot demonstration enterprise in intelligent manufacturing in Yunnan Province.